logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Order CRaFT 2026
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
    • Managing Loss of Exclusivity Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
    • Cracking the Code 2.0
  • LINKS
  • CONTACT US
logo-top-r
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Order CRaFT 2026
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
    • Managing Loss of Exclusivity Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
    • Cracking the Code 2.0
  • LINKS
  • CONTACT US

RWE and OBA Working Group 2019 Findings & Executive Summary

November 26, 2019
-
Market Access News, Publications
-
Posted by MORSE - < 1 min read.

The 2019 Real-World Evidence and Outcomes-Based Agreements Working Group research and outputs executive summary report is now available.

 

Download The Report

 

The mission of the Real-World Evidence and Outcomes-Based Agreements Working Group is to advance the opportunity for the use of outcomes-based agreements in Canada.

The working group’s 2019 primary focus was on research and analysis to bring clarity on the opportunity for OBAs in Canada, and to develop a framework for OBA implementation in Canada. Please direct any inquiries about this report to info@20sense.ca.

 

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

Share
Tags
CADTH
IHE
OBA
PBRSA
pCODR
pCPA
Reimbursement
Reimbursement strategy
RWD
RWE
← PREVIOUS POST
Summary of the CADTH Drug Portfolio Information Session November 2019
NEXT POST →
The workload at pCPA appears to have stabilized over 2019

Contact Us

MORSE Consulting Inc.

Toronto | Ottawa, Canada

+1-647-717-3179 (Toronto)

+1-613-864-8645 (Ottawa)

info@morseconsulting.ca

CTC Event Vancouver

Carcking the code Vancouver

Pre-order 2026 Report

2025 Canadian Reimbursement and Forecasting Timelines Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
Social
Connect & Follow:
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2026 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
RWE and OBA Working Group 2019 Findings & Executive Summary
Learn More
Learn More

You're viewing an older edition

The latest CRaFT 2026 report has updated reimbursement data, forecasts, and trends. Get the most current insights.

View the 2026 CRaFT Report → Go to homepage